The human recombining erithropoietin has been recently authorized in our country for patients programmed for orthopedic elective surgery with the objective of dimininshing the exposition to allogenic blood transfusions. The case that concerns us has to do with a patient that received 300 UI/kg/day of Eprex® (alpha Epoetinum) as apart of the treatment of the orthopedic trauma suffered and with the purpose of avoiding allogenic transfusions in the perioperarive period, given the negative of the patient to receive them because of being a Jehovah Witness
© 2001-2024 Fundación Dialnet · Todos los derechos reservados